AJOONI — Ajooni Biotech Income Statement
0.000.00%
Last trade - 00:00
- IN₹525.68m
- IN₹543.02m
- IN₹744.88m
- 15
- 48
- 66
- 35
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 397 | 400 | 510 | 740 | 745 |
Cost of Revenue | |||||
Gross Profit | 32.5 | 51.2 | 80.3 | 100 | 87.5 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 395 | 393 | 500 | 721 | 727 |
Operating Profit | 2.43 | 7.49 | 10.7 | 19.7 | 17.6 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 4.75 | 4.81 | 5.04 | 14.6 | 15.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | 4.11 | 3.47 | 3.73 | 10.5 | 11.2 |
Net Income Before Extraordinary Items | |||||
Net Income | 4.11 | 3.47 | 3.73 | 10.5 | 11.2 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 4.11 | 3.47 | 3.73 | 10.5 | 11.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.106 | 0.056 | 0.066 | 0.178 | 0.128 |